- Home
- INFU vs FENC Comparison
INFU vs FENC Comparison
Compare INFU & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INFU | FENC |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 276.3M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | INFU | FENC |
|---|---|---|
| Price | $8.38 | $7.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.50 | $13.50 |
| AVG Volume (30 Days) | 118.9K | ★ 183.3K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 271.43 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $141,054,000.00 | $38,790,000.00 |
| Revenue This Year | $8.82 | N/A |
| Revenue Next Year | $2.90 | $70.97 |
| P/E Ratio | $32.35 | ★ N/A |
| Revenue Growth | ★ 6.23 | N/A |
| 52 Week Low | $4.61 | $4.68 |
| 52 Week High | $11.04 | $9.92 |
Technical Indicators
Market Signals| Indicator | INFU | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 31.73 | 47.61 |
| Support Level | $8.71 | $7.51 |
| Resistance Level | $9.03 | $8.16 |
| Average True Range (ATR) | 0.32 | 0.33 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 1.15 | 36.24 |
Price Performance
Historical ComparisonAbout INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.